Journal
CURRENT MOLECULAR MEDICINE
Volume 13, Issue 10, Pages 1523-1537Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1566524013666131111120951
Keywords
Antibody; drug delivery; magnetic resonance imaging (MRI); near-infrared fluorescence (NIRF) imaging; photoacoustic tomography (PAT); positron emission tomography (PET); radioimmunoscintigraphy (RIS); single-photon emission computed tomography (SPECT)
Categories
Funding
- University of Wisconsin Carbone Cancer Center
- Department of Defense [W81XWH-11-1-0644]
- National Center for Advancing Translational Sciences (NCATS) [9U54TR000021]
- Elsa U. Pardee Foundation
Ask authors/readers for more resources
Human epidermal growth factor receptor-2 (HER-2) mediates a number of important cellular activities, and is up-regulated in a diverse set of cancer cell lines, especially breast cancer. Accordingly, HER-2 has been regarded as a common drug target in cancer therapy. Antibodies can serve as ideal candidates for targeted tumor imaging and drug delivery, due to their inherent affinity and specificity. Advanced by the development of a wide variety of imaging techniques, antibody-based imaging of HER-2 can allow for early detection and localization of tumors, as well as monitoring of drug delivery and tissue's response to drug treatment. In this review article, antibody-based imaging of HER-2 are summarized and discussed, with an emphasis on the involved imaging methods.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
